The purpose of this study was to compare early and late clinical outcomes in diabetic and nondiabetic patients after stent implantation in saphenous vein grafts (SVG). BACKGROUND Patients with diabetes mellitus have less favorable acute and long-term outcomes after stent implantation in native coronary arteries. The impact of diabetes on SVG stenting, however, is not known.
Patients with diabetes mellitus are at increased risk of restenosis after balloon angioplasty resulting in increased late morbidity and mortality compared with nondiabetic patients (1) (2) (3) . Two large randomized trials have shown that coronary stents improve procedural outcome and reduce restenosis in focal de novo native coronary artery lesions compared with balloon angioplasty (4, 5) . Although stents may improve results compared with balloon angioplasty in diabetic patients (6) , these patients still have increased incidence of complications and in-stent restenosis compared with nondiabetic patients (7) (8) (9) . Despite the fact that several studies have examined the impact of diabetes mellitus on short and long-term clinical outcomes after stent implantation in native coronary arteries (7) (8) (9) , little is known about the influence of diabetes after stent implantation in saphenous vein grafts (SVGs).
In order to evaluate the impact of diabetes on the acute and late clinical outcomes in a consecutive series of patients undergoing stent implantation in SVG, we compared inhospital and one-year clinical outcomes among nondiabetic and diabetic patients, and within the diabetic group, between patients requiring insulin therapy or oral hypoglycemic agents.
if they required insulin or oral hypoglycemic treatment at the time of initial interventional procedure.
Baseline clinical demographics and in-hospital events were confirmed by independent chart review. Clinical outcomes at one year were obtained by serial telephone interviews at one, three, six and 12 months by research nurses. Any late clinical events (death, Q-wave myocardial infarction [MI] , target lesion revascularization [TLR] , any angioplasty or bypass surgery [CABG] ) were adjudicated and corroborated by accompanying source documentation by a dedicated data coordinating center. In addition to TLR, target vessel revascularization rate is also reported. Stent types and deployment techniques. The types of stents used were either coronary (n ϭ 574, 33.6%) or "biliary" (n ϭ 1,132, 66.4%) tubular slotted stents (PalmazSchatz type). Coronary stents were used for vessels Ͻ4 mm in diameter, and the larger biliary type stents were reserved for vessels Ͼ4 mm in diameter. Details of the stent design and implantation technique have been previously described (4, 5) . Optimal stent implantation was carefully monitored using an interactive technique with on-line intravascular ultrasound (IVUS) interpretation in Ͼ90% of the cases. Atheroablation was performed in 361 (26.4%) lesions before stent implantation. All patients received 325 mg of aspirin before the procedure and continued indefinitely. After the stent placement, Ticlopidine (250 mg twice daily) was given to all patients for four weeks. Glycoprotein IIb/IIIa inhibitors were used in Ͻ3% of the patients in all treatment groups. Angiographic and IVUS analysis. Angiographic analysis was performed using a validated, automated edge-detection algorithm (CMS, MEDIS, Leiden, the Netherlands) as previously described (10) .
Intravascular ultrasound studies were performed after intragraft injection of 200 g of nitroglycerin with a commercially available scanner (Boston Scientific Corporation/Cardiovascular Imaging System, Maple Grove, Minnesota).
The Core Laboratory at the Washington Hospital Center analyzed the IVUS studies. Using computer planimetry (TapeMeasure, Indec System, Mountain View, California), lesion site and reference segment external elastic membrane (EEM) cross-sectional area (CSA), lumen CSA and plaque plus media were measured according to the validated protocols (11) (12) (13) . Statistical analysis. Statistical analysis was performed using StatView 4.5 or SAS (SAS Institute, Cary, North Carolina). Continuous variables are presented as mean Ϯ 1 standard deviation and were compared using unpaired t test. Categorical variables are presented as percent frequencies, and comparison between groups was performed using chisquare test. Stepwise regression analysis was used to determine whether diabetes was an independent predictor of in-hospital mortality. Cox proportional hazard regression analysis (14) was used to assess the relative risk of diabetes and other clinical, morphological and procedural variables on death, TLR and other adverse cardiac events at one-year follow-up. First, univariate logistic regression analysis was performed, and then variables with a p value of Ͻ0.2 were entered into the Cox model. These variables included age, gender, presence of diabetes, hypertension, previous history of MI, graft age, restenotic lesions, ostial lesion location, lesion length, prestent atheroablation, type of stents, preprocedural and final reference diameter, minimal lumen diameter before and after intervention and final lesion CSA by IVUS.
Cumulative event-free survival curves were calculated and displayed using the SAS LIFE test analysis. The Wilcoxon log rank test was used for survival comparison between groups (diabetic vs. nondiabetic patients and diabetic patients requiring insulin vs. oral hypoglycemic treatment). Values of p Ͻ0.05 were accepted as significant.
Abbreviations and Acronyms
CABG ϭ coronary artery bypass surgery CI ϭ confidence interval CSA ϭ cross-sectional area EEM ϭ external elastic membrane IVUS ϭ intravascular ultrasound MI ϭ myocardial infarction RR ϭ relative risk SVG ϭ saphenous vein graft TLR ϭ target lesion revascularization more degenerated SVG compared with noninsulinrequiring diabetic patients or nondiabetic patients. Thrombus containing lesions were more common in nondiabetic as compared with diabetic patients. The incidence of postprocedural angiographic complications, such as distal embolization, thrombus and no reflow, was similar between diabetic and nondiabetic patients and within the diabetic group. By quantitative coronary angiography, preprocedural and postprocedure measurements were similar for both nondiabetic and diabetic patients except for postintervention minimum lumen diameter, which was larger in diabetic patients requiring insulin treatment (3.2 Ϯ 0.67 mm) compared with diabetic patients treated with oral hypoglycemic agents (3.0 Ϯ 0.63 mm; p ϭ 0.05), with no difference between diabetic and nondiabetic patients.
IVUS results.
Preintervention IVUS measurements were similar between diabetic and nondiabetic patients except for EEM CSA at the reference and lesion sites, which were significantly smaller in diabetic patients (Table 4) . After intervention, only the lesion site EEM CSA was significantly smaller in diabetic as compared with nondiabetic patients. There were no significant differences between diabetic patients requiring insulin or oral hypoglycemic treatment. In-hospital results. Overall procedural success was uniformly high in all groups (Table 5 ). However, combined major in-hospital complications (death, Q-wave MI and emergent CABG) were more frequent in diabetic as compared with nondiabetic patients (4.7% vs. 2.2%; p ϭ 0.02), with no difference between diabetic patients requiring insulin or oral hypoglycemic treatment (p ϭ 0.69). In-hospital CSA ϭ cross-sectional area; CSN ϭ cross-sectional narrowing; EEM ϭ external elastic membrane; IRDM ϭ insulin-requiring diabetics; MLD ϭ mininum luminal diameter; NIRDM ϭ noninsulin-requiring diabetics; PϩM ϭ plaque plus media. Similarly, the overall cardiac event rate (death, Q-wave MI, TLR and any revascularization) was also higher in diabetic compared with nondiabetic patients (32.9% vs. 21.5%, p ϭ 0.001). Patients with diabetes more often underwent repeat angioplasty (13.6% vs. 9.6%, p ϭ 0.02) than patients without diabetes. The cumulative death rate at one year was 12.3% for diabetic and 5% for nondiabetic patients (p ϭ 0.001). Cardiac event-free survival (freedom from death, Q-wave MI, angioplasty or CABG) at one year was 68% in diabetic patients, significantly lower compared with 79% in nondiabetic patients (p ϭ 0.0003), with no subgroup difference between the two diabetic populations (64% vs. 65%, p ϭ 0.31). Actuarial cardiac event-free survival curves for any cardiac event and for TLR between diabetic and nondiabetic patients and between diabetic patients requiring insulin or oral hypoglycemic treatment are shown in Figures  1 and 2 , respectively. Cox regression analysis was used to identify the independent predictors of any major adverse cardiac events (death, Q-wave MI, angioplasty or CABG) and TLR at one-year follow-up. Independent predictors of TLR were presence of diabetes (relative risk [RR]: 1.23; CI: 0.96 to 1.58; p ϭ 
DISCUSSION
This study shows that diabetic patients compared with nondiabetic patients undergoing stent implantation in SVG have: 1) higher in-hospital and late mortality, 2) higher one-year target lesion revascularization rates, and 3) significantly lower one-year cardiac event-free survival. In this study we also found that the presence of diabetes and prestent atheroablation are the independent predictors of clinical restenosis, whereas hypertension, presence of diabetes, history of MI, final reference diameter and prestent atheroablation are predictive for composite cardiac events. Treatment of SVG disease. Balloon angioplasty of SVG has been limited by frequent periprocedural complications and high incidence of late restenosis (15, 16) . Repeat CABG is associated with increased morbidity and mortality and provides less symptomatic relief as compared with initial operation (17, 18) . Several studies have reported favorable results of stent implantation in the SVG lesions (19 -22) . In the large multicenter U.S. Palmaz-Schatz stent series in SVG lesions, Wong et al. (20) demonstrated that stent implantation in patients with focal SVG lesions is associated with high deployment and procedural success, excellent angiographic results, acceptable complications, six months angiographic restenosis of 29.7% and favorable late clinical outcome. Likewise, in a randomized comparison of stents and balloon angioplasty Savage et al. (23) have demonstrated angiographic success in 97% of the patients in the stent group and 86% of the patients in the balloon group Figure 2 . Actuarial event-free survival curves for any adverse cardiac events (death, Q-wave infarction, angioplasty and coronary artery bypass surgery, top) and TLR (bottom) for 12 months after stenting in patients with insulin-requiring diabetes versus noninsulin-requiring diabetes (on oral hypoglycemic agents). IRDM ϭ insulin-requiring diabetics; NIRDM ϭ noninsulin-requiring diabetics; TLR ϭ target lesion revascularization.
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(p Ͻ 0.001). Restenosis occurred in 46% of the patients assigned to balloon angioplasty and in 37% of the patients in the stent group. In our study procedural success was achieved in over 97% of the patients, which is similar to above studies. The overall (including both diabetic and nondiabetic patients) event-free survival in this study (73%) is also comparable to the above studies (76.3% and 73%, respectively). However, in studies by Wong et al. (20) and Savage et al. (23) , patients with only focal lesions were treated with stent implantation, whereas in this study both focal and diffuse lesions were included. Unlike previous reports, the clinical restenosis rate in this study was significantly lower. This lower rate may be related to improved stent techniques, use of IVUS guidance or more effective antiplatelet therapy, as the percentage of diabetic patients was similar among the studies. Finally, although the patient cohort in the above studies included diabetic patients, there was no distinction made between diabetic and nondiabetic patients in terms of in-hospital and late clinical outcomes. Diabetes and coronary artery stenting. Diabetes remains an independent risk factor for worse clinical and angiographic outcomes after both balloon angioplasty and stenting in native coronary arteries (1, 2, 7, 8) . Analysis from the Bypass Angioplasty Revascularization Investigation (24) trial showed worse five-year survival rates in diabetic patients with multivessel disease treated by balloon angioplasty compared with those undergoing bypass surgery. In the study by Stein et al. (2) , the five-year survival rate was 89% in diabetic versus 93% in nondiabetic patients. Likewise, Kip and colleagues (1) reported a nine-year survival rate of 64% in diabetic and 82% in nondiabetic patients (p Ͻ 0.0001). In another study, Carrozza et al. (7) found increased late loss and greater incidence of restenosis among diabetic patients after coronary artery stenting as compared with nondiabetic patients (55% vs. 20%, p ϭ 0.001). Although in this study 54% of the lesions were in SVG, there were a relatively small number of diabetic patients (n ϭ 37). In none of the above studies was the effect of diabetes studied after stent implantation in pure SVG population.
In this study high procedural success was achieved in both diabetic and nondiabetic patients. Similarly there was no difference in the incidence of procedure-related non-Qwave MI (creatine kinase isoenzyme Ն5 times normal value), distal embolization and subacute stent thrombosis in both treatment groups. However, in-hospital mortality was significantly higher in diabetic as compared with nondiabetic patients. This high prevalence of in-hospital mortality could be related to the presence of complex SVG lesion morphology, generalized atherosclerotic disease, reduced left ventricular function and frequently associated comorbid conditions in diabetic patients. However, diabetes mellitus was the sole independent predictor of in-hospital mortality by multivariate regression analysis.
During follow-up the overall clinical outcome was worse for diabetic patients due to higher rates of TLR (16.6% vs.
12.3%, p ϭ 0.001) and increased one-year mortality (12.3% vs. 5%, p ϭ 0.001). Consequently, diabetic patients had lower event-free survival (67% vs. 79%; p ϭ 0.0003). Several previous studies have indicated diabetes to be an independent predictor of increased late mortality. Elezi et al. (8) reported a significantly lower event-free survival in diabetic patients after coronary artery stenting. A Cox proportional hazard model in that study showed that diabetes correlated strongly with late mortality. Abizaid et al. (9) in their study also found diabetes to be independently associated with higher late mortality after native coronary artery stenting. Cox proportional hazard regression analysis in our study also identified diabetes to be an independent predictor of one-year cumulative mortality. This increased risk was independent of other comorbid conditions, indicating a significant influence of diabetes for a worse one-year outcome in patients undergoing SVG stenting. It is interesting that prestent atheroablation was an independent predictor of both TLR and late cardiac events in our study. One plausible explanation could be that the lesions requiring atheroablation had more unfavorable baseline lesion characteristics, such as thrombus or degeneration, prompting the operators to use prestent atheroablation with the hope of avoiding acute complications. This finding is in contradistinction to a report in native coronary arteries, where directional atherectomy before stenting resulted in favorable late outcome (25) . These results are not conflicting, however, as there are inherent differences between the native and SVG lesions (26) . The final reference diameter (average of the proximal and distal reference segments, which is usually larger and more accurate for reference vessel size than the preintervention reference due to underperfusion of the distal segment before intervention) had a protective effect on late outcome, suggesting that the larger veins may provide more room for late neointima or thrombus. The incidence of late Q-wave MI was similar between diabetic and nondiabetic patients (2.5% vs. 1.8%, p ϭ 0.26).
Thus, the findings in this study suggest that, although the stents appear to equalize the acute angiographic results in SVG patients regardless of their diabetic status, they do not eliminate the increased risk of in-hospital mortality and adverse long-term outcomes that diabetic patients experience after SVG interventions. Study limitations. There are several limitations to this study. First, only the lesions treated with Palmaz-Schatz stents were included in the analysis. Thus, we cannot compare different stent designs or evaluate newer stents, which may have properties better suited for the treatment of SVG lesions. Second, the relative impact of diabetes mellitus on the clinical outcome after SVG stenting was not studied prospectively, but was rather based on clinical and angiographic data derived from a large group of consecutively studied patients. The relatively small group of insulinrequiring diabetic patients analyzed may have resulted in type II statistical errors when comparing the clinical outcome to those in noninsulin requiring diabetic group.
Finally, the follow-up was intentionally truncated at one year, and long-term follow-up may have produced different results as vein graft failure continues to develop with time. Despite these limitations, this study provides clinically relevant information regarding the detrimental impact of diabetes mellitus on the acute and late outcomes in patients undergoing stent implantation in SVG. Conclusions. In this large series of consecutive patients undergoing stent implantation in SVG, diabetic patients compared with nondiabetic patients had: 1) similar inhospital procedural success rates, 2) higher in-hospital and late mortality, 3) higher one year TLR rates, and 4) lower cardiac event-free survival at one-year follow-up.
